Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER 14UNKNOWN 1INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 5Sarcoma 1Lymphoid 1Gastrointestinal 1CNS 1

Conditions

Esophageal Neoplasms 1

Interventions

Gemcitabine 302Fluorouracil 296Oxaliplatin 269Bevacizumab 267Capecitabine 233Leucovorin 229pembrolizumab 215Irinotecan 185Cisplatin 142Cetuximab 142Nivolumab 131Paclitaxel 117130-nm albumin-bound paclitaxel 117Sorafenib 86Albumin-Bound Paclitaxel 75Docetaxel 65regorafenib 64atezolizumab 64IFL protocol 61Folfox protocol 61Trastuzumab 55Panitumumab 47durvalumab 46Ramucirumab 43Injections 43Sunitinib 41Drug Therapy 41Carboplatin 40trifluridine tipiracil drug combination 38lenvatinib 38

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × endostar protein × Gastrointestinal × Clear all
NCT01368419 2013-04-24

Continuous Endostar Infusion Combined With Radiotherapy in Esophageal Cancer Patients

Jiangsu Simcere Pharmaceutical Co., Ltd.

Phase 2 Unknown
40 enrolled
Gastrointestinal

Esophageal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡